Myriad Genetics, Inc.

560 articles with Myriad Genetics, Inc.

• Myriad Genetics Expands Board of Directors with New MemberRashmi Kumar Elected to Myriad’s Board of Directors

  9/10/2020

  Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the election of Rashmi Kumar, age 51, to its Board of Directors, effective immediately, expanding the Board to 12 members.  Additionally, Ms. Kumar was appointed to the Audit and Finance Committee of Myriad’s Board. Ms. Kumar is Senior Vice President and Global Chief Information Officer of Hewlett

• American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer

  8/21/2020

  Myriad Genetics, Inc., a global leader in molecular diagnostics and precision medicine, announced that the American Society of Clinical Oncology has exclusively included Myriad’s myChoice® CDx test in its new recommendations on the use of PARP inhibitors for the treatment and management of certain patients with advanced ovarian cancer.

• Myriad Genetics Announces Inducement Awards

  8/14/2020

  Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced that in connection with the previously announced appointment of Paul J. Diaz as President and Chief Executive Officer of the Company, effective yesterday, August 13, 2020, the Company’s Board of Directors authorized the grant to Mr. Diaz of (i) a restricted stock unit award for 298,954 shares of the C

• Myriad Genetics Reports Fiscal Fourth-Quarter 2020 Financial Results

  8/13/2020

  Test Volumes Improved Meaningfully By the End of the Fourth Quarter Following Substantial Declines in March and April Due to the Initiation of Social Distancing Policies Total Fourth-Quarter Revenues of $93.2 Million Fourth-Quarter Diluted EPS of ($0.74) and Adjusted EPS of ($0.31) SALT LAKE CITY, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced financia

• Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors

  8/13/2020

  Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the appointment of Paul J. Diaz as President and Chief Executive Officer, effective August 13, 2020.

• New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions

  8/10/2020

  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today a new study published in the peer-reviewed journal Genetics in Medicine demonstrates the limitations of ethnicity-based medical guidelines in identifying couples at risk for a pregnancy affected by serious genetic conditions.

• Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020

  8/6/2020

  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal fourth-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m. EDT on Thursday, August 13, 2020.  During the call, R. Bryan Riggsbee, interim president and CEO and chief financial officer, and Scott Gleason, senior vice president of Investor Relations and Corporate Strategy, will

• Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer

  7/31/2020

  Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that Medicare has expanded coverage for BRACAnalysis® CDx for men with prostate cancer who are eligible or may become eligible for treatment Lynparza®.

• Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS Test

  7/29/2020

  Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that the company has launched its proprietary AMPLIFY™ technology, which further increases the performance of its Prequel™ noninvasive prenatal screening test.

• Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra®

  7/28/2020

  Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that the company has launched a new enhancement that is now available on its Vectra® test report.

• Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D.

  7/22/2020

  Daniel M. Skovronsky, M.D., Ph.D. Elected to Myriad’s Board of Directors. Walter (Wally) Gilbert, Ph.D., announces upcoming retirement from the Board of Directors

• Myriad Announces New Studies Validating the Ability of Myriad’s riskScore® Test to Modify Breast Cancer Risk Prediction

  7/7/2020

  Publications Demonstrate the Ability of the PRS Component of riskScore® to Accurately Stratify Breast Cancer Risk in Women Both With and Without Pathogenic Mutations

• Myriad Announces Partnership with OptraHEALTH® to Deliver “Gene™” a New AI Based Information Tool for Hereditary Cancer Patients

  7/6/2020

  Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced a new collaboration with OptraHEALTH® to implement a cognitive ChatBOT named Gene™ to provide genetic and financial assistance information to prospective patients.

• Myriad Launches New GeneSight® Psychotropic Patient Collection KitClinicians Seeing Patients Remotely Can Now Offer Home DNA Sample Collection

  7/1/2020

  Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced the launch of a new patient home collection kit for the GeneSight® Psychotropic test.

• New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment

  6/25/2020

  Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that a new study published in Future Medicine demonstrates the ability of myPath® Melanoma to accurately classify skin lesions ruled indeterminate by standard pathological review.

• Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National Provider

  6/15/2020

  Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that the company has received favorable coverage decisions for Prolaris® from three new commercial health plans including one of the top five national providers of health insurance.

• Palmetto GBA Issues Final Local Coverage Determination on Pharmacogenomic Testing for Medicare BeneficiariesNew LCD Provides Coverage for PGx Testing Across a Broad Range of Providers and Psychiatric Conditions

  6/11/2020

  Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, acknowledges the release of a final local coverage determination for pharmacogenomic testing by Palmetto GBA, one of the administrative contractors for the Centers for Medicare & Medicaid Services.

• New Study Demonstrates GeneSight Psychotropic Better Predicts Blood Drug Levels When Compared to Single-Gene TestingStudy Reviewed Citalopram and Escitalopram

  6/8/2020

  Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced a newly published study in Psychiatry Research.

• Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast CancerEndoPredict Predicts Response to Neoadjuvant Chemotherapy and Endocrine Therapy

  6/4/2020

  Myriad Genetics, Inc., a global leader in molecular diagnostics and precision medicine, announced the publication of a prospective study demonstrating that the EndoPredict® test predicts which patients with ER+, HER2- early-stage breast cancer will benefit from neoadjuvant therapy.

• Myriad Presents New Data at ASCO Validating the Ability of riskScore® to Provide Personalized Breast Cancer Risk Information to Patients

  5/29/2020

  Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced the presentation of two new studies at the 2020 American Society of Clinical Oncology annual meeting demonstrating the ability of Myriad’s riskScore® test to provide personalized breast cancer risk information that allows patients and physicians to make better informed clinical treatment decisions.